Medable Inc., a leading technology platform for agentic clinical development, today announced its Digital Data Flow Agent. The new solution automatically transforms static clinical trial protocols into structured, machine-readable data. As a result, it enables continuous data usage throughout the clinical development lifecycle. Traditionally, clinical trial protocols exist as static documents. These documents require significant manual review and interpretation across multiple downstream systems. However, Medable’s Digital Data Flow Agent changes this process by converting protocol information into CDISC USDM 4.0 standardized structured JSON data.
This machine-readable data foundation supports automated and adaptive clinical trial operations. Additionally, it helps organizations maintain consistency across various stages of clinical development. For instance, sponsors can use Medable’s Digital Data Flow Agent to automatically generate electronic clinical outcomes assessments (eCOAs) within minutes. Also, the solution ensures that generated eCOAs remain aligned with the original protocol and future protocol amendments. Therefore, clinical teams can reduce manual effort while improving accuracy throughout the study lifecycle.
Digital Data Flow Agent Supports Real-Time Clinical Trial Execution
As the healthcare industry moves toward adaptive and real-time clinical trial models, Medable’s Digital Data Flow Agent provides the infrastructure required for continuous protocol evolution. Approved protocol updates can automatically flow across connected documents, workflows, and clinical systems. This capability reduces operational complexity and allows organizations to respond faster to new study insights. The approach supports the U.S. Food and Drug Administration’s vision for real-time clinical trials. In this model, continuous data review becomes an essential part of clinical research operations. Therefore, maintaining consistency across study documentation and operational systems requires a digital and machine-readable foundation. Old document-based processes cannot fully support this evolving clinical environment.
Medable’s Digital Data Flow Agent represents a significant advancement toward enabling faster, more connected, and data-driven clinical trial execution.
“The FDA’s move toward real-time clinical trials makes clear that the industry can no longer rely on static documents and manual handoffs to support modern study execution,” said Jessica Dolfi, Medable Senior Vice President of Solution Consulting. “Medable’s DDF Agent helps create the machine-readable foundation needed to keep protocols, downstream systems, and operational workflows continuously aligned. That is essential for a future in which study data, endpoints, and safety signals must move with greater speed, consistency, and traceability to support real-time trial execution and responsiveness.”
Medable Advances Agentic AI for Clinical Development
Medable is applying agentic AI across the complete clinical development lifecycle, from protocol initiation to study close-out, through Medable Agent Studio. The purpose-built agentic AI platform enables sponsors and contract research organizations (CROs) to deploy AI agents across clinical workflows. Additionally, the platform combines no-code agent creation, human-in-the-loop oversight, GxP-ready compliance controls, and a clinical data ontology layer. Also, Medable Agent Studio includes built-in AI governance and Model Context Protocol connectors across clinical and enterprise systems. These capabilities help automate operational processes while maintaining transparency, auditability, and regulatory alignment. In addition, Medable’s Agentic Accelerator Program provides onboarding, integration support, and change management services. Therefore, customers can gain value from AI agents from day one while improving efficiency across clinical operations.
Explore Health Tech Insiders for the latest medical innovations and reliable strategic insights driving the future of technology-driven healthcare transformation.
News Source: Businesswire.com
